Multiple Types Of Heart Attacks Reduced By Prasugrel In TRITON-TIMI 38 Trial Investigators from the Phase III TRITON-TIMI 38 study applied the new classification system for the Universal Definition of Myocardial Infarction to the results of the study and showed that patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) and taking
Source: www.medicalnewstoday.comWorld-Renowned Urologist, J. Francois Eid, M.D., Lauds Improvements In Penile Prosthesis And Artificial Urinary Sphincter Technologies Dr. J. Francois Eid has performed more internal penile implant surgeries than anyone in the world and has built a reputation for excellence in the treatment of erectile dysfunction (ED).
Source: www.medicalnewstoday.comBayer Schering Pharma Presents Positive Results Of Phase II Study With Riociguat Positive data from a phase II trial with Bayer Schering Pharma's oral agent riociguat for the treatment of two different forms of pulmonary hypertension (PH); chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); were presented today at the American Thoracic Society (ATS) international conference in San Diego, USA.
Source: www.medicalnewstoday.comViagra4Woman.com Enhances Site with New Product and Blog Vigorelle is a new enhancement product that is being featured at Viagra4Woman.com, a year-old site dedicated to helping women increase their libido. Recently, the site's co-owner sat down to talk about the new product and the new blog he launched this month. (PRWeb May 22, 2009)
Read the full story at http://www.prweb.com/releases/2009/05/prweb2447824.htm
Source: www.prweb.comSucampo Initiates Pivotal Phase 3 Efficacy Trial Of Lubiprostone For Chronic Idiopathic Constipation In Japan Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), an international biopharmaceutical company, announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan. Under the terms of a license, commercialization and supply agreement Sucampo signed in February 2009 with Abbott Japan Co., Ltd.
Source: www.medicalnewstoday.comBioniche Phase III Clinical Trial With Urocidin(TM) Progressing Well Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.
Source: www.medicalnewstoday.comCutaneous Application Of Nanoparticles Offers Hope For Treatment Of Erectile Dysfunction Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Topical treatments for ED may offer localized therapeutic results with the benefit of lower dosage and the avoidance of adverse side effects due to systemic absorption.
Source: www.medicalnewstoday.comBoston Scientific Begins Clinical Trial For Next-Generation Nitinol Stent To Treat Iliac Artery Disease Boston Scientific Corporation (NYSE: BSX) announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient's lower extremities. The first U.S. patient was enrolled on May 14 by Nicolas W. Shammas, M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa.
Source: www.medicalnewstoday.comStudy Reported Tadalafil Taken Once Daily Improved Erectile Function In Men With ED And Sexual Quality Of Life In Couples Eli Lilly and Company (NYSE: LLY) announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-tolerated, improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners.
Source: www.medicalnewstoday.comPARI Pharma's Nebulized DSCG Shows Results Similar To Inhaled Steroids In Asthma Studies Presented At ATS This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma's inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma. Results showed decreases in mean asthma symptom scores without a change in lung function for both groups.
Source: www.medicalnewstoday.com
# posted by Network @ 11:44 PM
